Cargando…

Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review

Long‐term follow‐up of multiple myeloma (MM) clinical trials are needed to assess long‐term outcomes. We aimed to investigate the length of follow‐up of all phase III MM clinical trials. Median follow‐up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Mohammad O., Abdullah, Hafez M., Obeidat, Khaldun, Chakraborty, Rajshekhar, Al Hadidi, Samer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435726/ https://www.ncbi.nlm.nih.gov/pubmed/37601879 http://dx.doi.org/10.1002/jha2.680

Ejemplares similares

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Gender disparities in multiple myeloma publications
por: Dweik, Aala, et al.
Publicado: (2022)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture
por: Al Hadidi, Samer, et al.
Publicado: (2017)

Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
por: Hussain, Munawwar, et al.
Publicado: (2023)

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
por: Shrivastava, Trilok, et al.
Publicado: (2023)

Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review
por: Anampa-Guzmán, Andrea, et al.
Publicado: (2022)

Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials
por: Htut, Thura W., et al.
Publicado: (2020)

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma
por: Al Hadidi, Samer, et al.
Publicado: (2023)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma
por: Biran, Noa, et al.
Publicado: (2021)

IgE multiple myeloma: detection and follow-up
por: Nafría Jiménez, Beatriz, et al.
Publicado: (2021)

Sleep duration and breast cancer risk in the Breast Cancer Detection Demonstration Project follow-up cohort
por: Qian, X, et al.
Publicado: (2015)

Determination and Quantification of the Vinblastine Content in Purple, Red, and White Catharanthus Roseus Leaves Using RP-HPLC Method
por: Abdul Rahim, Rohanizah, et al.
Publicado: (2018)

Can Hydroxychloroquine Cause G6PD-Related Hemolysis? A Case Study
por: Obeidat, Khaldun, et al.
Publicado: (2020)

Imatinib-Induced Tremor in a Patient with Chronic Myeloid Leukemia in Chronic Phase
por: Obeidat, Khaldun, et al.
Publicado: (2019)

Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma
por: Norton, Samuel E, et al.
Publicado: (2023)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

Influence of metformin on HIF-1 pathway in multiple myeloma
por: Kocemba-Pilarczyk, Kinga A., et al.
Publicado: (2020)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Multiple Myeloma Index for Risk of Infection
por: T, Valkovic, et al.
Publicado: (2018)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Initial evaluation of [(18)F]-FACBC for PET imaging of multiple myeloma
por: Morath, Volker, et al.
Publicado: (2022)

Use of daratumumab in high risk multiple myeloma: A meta‐analysis
por: Premkumar, Vikram, et al.
Publicado: (2020)

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
por: Lin, Yi, et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development
por: Iftikhar, Ahmad, et al.
Publicado: (2019)

Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls
por: Mustafa, S. Shahzad, et al.
Publicado: (2018)

CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment
por: Abecassis, Audrey, et al.
Publicado: (2022)

The Role of DNA Repair in Genomic Instability of Multiple Myeloma
por: Ali, Jana Yasser Hafez, et al.
Publicado: (2022)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Dimopoulos, Meletios A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9f8ovrh7fprad8cqjplok91153